Tetraneuron receives approval to initiate first-in-human clinical testing of TET-101 in Alzheimer’s disease patients in Australia
Australia authorises the clinical evaluation of TET-101, Tetraneuron’s E2F4DN-based gene therapy programme with the potential to slow neurodegeneration and restore cognitive functions affected by Alzheimer’s disease. Madrid, 17 June 2026 —Tetraneuron, a Spanish biotechnology company focused on the development of gene therapies for neurodegenerative diseases, announces that it has received approval to proceed with first-in-human … Read more